Zusammenfassung
Granulosazelltumoren sind seltene Tumoren und machen einen Anteil von etwa 2 - 3 %
aller Ovarialtumoren aus. Auch wenn sich der Granulosazelltumor sowohl tumorbiologisch
als auch prognostisch von den epithelialen Tumoren abgrenzen lässt, orientiert sich
die Therapie an den Empfehlungen zum Ovarialkarzinom. Methodik: Im Rahmen einer multizentrischen, retrospektiven Studie wurden die Krankheitsverläufe
von 25 Patientinnen mit einem histologisch gesicherten Granulosazelltumor des Ovars
analysiert, die eine systemische Chemotherapie erhielten.Ergebnisse: Das mediane Alter der Patientinnen zum Zeitpunkt der Chemotherapie lag bei 51 Jahren
(Spannbreite 26 - 75 Jahre). Hierzu zählten neun Patientinnen mit Stadium I, neun
Patientinnen mit Stadium II - IV und sieben Patientinnen wurden in der Rezidivsituation
behandelt. Das mediane Follow-up betrug 98 Monate (Spannbreite 6 - 189 Monate). Insgesamt
wurden neun verschiedene Therapieregime eingesetzt, wobei nur in einem Fall diese
als Monotherapie erfolgte. Bei 60 % der Patientinnen wurden platinhaltige Kombinationen
appliziert. Die Überlebenszeiten zwischen der Behandlung mit platinhaltigen versus
nichtplatinhaltigen Substanzen erwiesen sich als nicht signifikant unterschiedlich
(p = 0,3). Diese Aussage ist jedoch aufgrund der sehr kleinen Fallzahl erheblich eingeschränkt.
Das mittlere Gesamtüberleben aller Patientinnen, die eine Chemotherapie erhalten hatten,
lag bei 96,6 Monaten (95 %-CI: 78,22 - 115,04 Monate), wobei das mediane Gesamtüberleben
nicht erreicht wurde. Das mittlere Gesamtüberleben der Patientinnen mit fortgeschrittenem
Tumorstadium oder Rezidiv lag bei 81,4 Monaten (95 %-CI: 53,8 - 108,9 Monate). Das
mediane Gesamtüberleben wurde hierbei nicht erreicht. Schlussfolgerungen: Wegen der Seltenheit von Granulosazelltumoren sollte eine zentrale Datenerfassung
erfolgen, die dann die Grundlage für die Konzeption von multizentrischen adjuvanten
Studien sein können.
Abstract
Purpose Granulosa cell tumors account for 2 - 3 % of ovarian malignancies. Treatment
recommendations are based loosely on those for ovarian carcinoma, although the two
entitites differ considerably in tumor biology and prognosis. Methods: We reviewed 25 women (median age, 51 years; range, 26 - 75) who received chemotherapy
after surgery for ovarian granulosa cell tumors. Eighteen patients received adjuvant
chemotherapy as a component of primary treatment (9 FIGO stage I, 9 stage II - IV)
and seven after recurrence. Nine chemotherapy regimens were used and 15 patients received
platinum-based regimens. Results: The median follow-up was 98 months (range, 6 - 189). Although the number of patients
was small, there was no significant difference in overall survival between patients
who received platinum-based regimens and those who received chemotherapy without platinum.
The average overall survival was 96.6 months (95 % CI, 78 - 115). The average overall
survival of women with stage II - IV disease or recurrence was 81.4 months (95 % CI,
54 - 109). Conclusion: The rarity of ovarian granulsa cell tumors suggests a need for a central registry
and prospective studies to compare chemotherapy regimens.
Schlüsselwörter
Granulosazelltumor - Ovarialtumor - Chemotherapie - Langzeitergebnisse
Key words
Granulosa cell tumor - tumor of the ovary - chemotherapy - long term follow-up
Literatur
1
Rokitansky C V.
Über Abnormalitäten des Corpus luteum.
Wien Med Ztg.
1859;
1
253-254
2
Björkholm E.
Granulosa cell tumor: A comparison of survival in patients and matched controls.
Am J Obstet Gynecol.
1980;
138
329-331
3
Evans A T, Gaffey T A, Malkasian G D, Annegers J F.
Clinicopathological review of 118 granulosa and 82 theca cell tumors.
Obstet Gynecol.
1980;
55
231-238
4
Fox H, Langly F A.
A clinicopathological study of 92 cases of granulosa cell tumors of the ovary with
special reference to factors influencing prognosis.
Cancer.
1975;
35
231-241
5
Malmström H, Hogberg T, Risberg B, Simonsen E.
Granulosa cell tumors of the ovary: prognostic factors and outcome.
Gynecol Oncol.
1994;
52
50-55
6
Ohel G, Kaneti H, Schenker J G.
Granulosa cell tumors in Israel: A study of 172 cases.
Gynecol Oncol.
1983;
15
278-286
7
Gee D C, Russel P.
The pathological assessment of ovarian neoplasms. IV: The sex cord stromal tumors.
Pathology.
1981;
13
235-255
8 Scully R E.
Sex cord-mesenchyme tumours. Pathologic classification and its relation to prognosis
and treatment. Gentil F Ovarian Cancer. Heidelberg; Springer-Verlag 1962
9
Segal R, De Petrillo A D, Thomas G.
Clinical review of adult granulosa cell tumors of the ovary.
Gynecol Oncol.
1995;
56
338-344
10 Young R H, Scully R E.
Sex cord-stromal, steroid cell and other ovarian tumors with endocrine, paraendocrine,
and neoplastic manifestations. Kurmann RJ Blaustein, Pathology of the Female Genital Tract. 4th ed. Springer 1994:
783-847
11 Serov S, Scully R E, Sobin L H.
Histological typing of ovarian tumours. World Health Organization International Histological Classification of Tumours. 9th
ed. Geneva; WHO 1973
12
Dietel M, Hauptmann S.
Die neue WHO-Klassifikation der Ovarialtumoren: Darstellung und Kommentar.
Geburtsh Frauenheilk.
2000;
60
177-181
13
Abu-Yousef M.
Case 5: Gynecological granulosa cell tumor of the ovary with endometrial carcinoma.
J Ultrasound Med.
2000;
19
357
14
von Georgi R, Münstedt K.
Ein multifaktorielles Modell zur Ätiologie des Ovarialkarzinoms.
Geburtsh Frauenheilk.
2002;
62
1060-1068
15
Calaminus G, Wessalowski R, Harms D, Gobel U.
Juvenile granulosa cell tumors of the ovary in children and adolescents: results from
33 patients registered in a prospective cooperative study.
Gynecol Oncol.
1997;
65
447-452
16 Colombo N.
Management of sex cord-stromal tumors. Gershenson DM Ovarian Cancer. New York; Churchill Livingstone 1998: 417
17
Fervers B, Kebrat P, Guastalla J P. et al .
Standards, options and recommendations: Clinical practice guidelines for diagnosis,
treatment and follow-up in epithelial ovarian cancer.
An Oncol.
2000;
11
84
18 Kuhn W.
Maligne Ovarialtumoren. Deutsche Krebsgesellschaft, Informationszentrum für Standards in der Onkologie. http://www.krebsgesellschaft.de
2001
19
Du Bois A, Pfisterer J, Kellermann L, Kreienberg R.
Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss
hat die Teilnahme an klinischen Studien?.
Geburtsh Frauenheilk.
2001;
61
863-871
20
Pankratz E, Boyes D A, White G W, Galliford B W, Fairey R N, Benedet J L.
Granulosa cell tumors.
Obstet Gynecol.
1978;
52
718-723
21
Colombo N, Sessa C, Landoni F, Sartori E, Pecorelli S, Mangioni C.
Cisplatin, vinblastin, and bleomycin combination chemotherapy in metastatic granulosa
cell tumor of the ovary.
Obstet Gynecol.
1986;
67
265-268
22
Kaye S B, Davies E.
Cyclophosphamide adriamycin and cis-platin for the treatment of advanced granulosa
cell tumor, using serum estradiol as a tumor marker.
Gynecol Oncol.
1984;
24
261-264
23
Gershenson D M, Copeland L J, Kavanagh J J, Stringer A C, Saul P B, Wharton J T.
Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and
cyclophosphamide.
Gynecol Oncol.
1987;
70
765-769
24
Kietlinska Z, Pietrzak K, Drabik M.
The management of granulosa cell tumors of the ovary based on long term follow up.
Eur J Gynecol Oncol.
1993;
14
118-127
25
Alberti W, Bamberg M, Schulz U.
Granulosazelltumoren.
Dtsch med Wschr.
1984;
109
750-752
26
Smith J P, Day A J.
Review of ovarian cancer at the University of Texas systems cancer center, M. D. Anderson
Hospital and tumor institute.
Am J Obstet Gynecol.
1999;
135
984-993
27
Neville A J, Kennedy W G, Davis T E.
The chemotherapy of granulosa cell tumors of the ovary: experience of the Wisconsin
Clinical Cancer Center.
Med Ped Oncol.
1984;
12
397-400
28
Lee I-W, Levin W, Chapman W, Goldberg R EA, Murphy K J, Milosevic M.
Radiotherapy for the treatment of metastatic granulosa cell tumor in the mediastinum:
a case report.
Gynecol Oncol.
1999;
73
455-460
29
Björkholm E.
Granulosa-cell and theca-cell tumor. The clinical picture and long term out-come for
the Radiumhemmet series.
Acta Obstet Gynecol Scand.
1980;
59
361
30
Kalavathi N.
Granulosa cell tumour - hormonal aspects and radiosensitivity.
Clin Radiol.
1971;
22
524-527
31
Engle E B.
Roentgen treatment of granulosa cell carcinoma of the ovary.
Amer J Roentgenol.
1958;
80
793
32
Malkasian G D, Webb M K, Jorgenson E O.
Observations on chemotherapy of granulosa cell carcinomas and malignant ovarian teratomas.
Obstet Gynecol.
1974;
44
885-888
33
Smith J P, Rutledge F.
Chemotherapy in the treatment of carcinoma of the ovary.
Am J Obstet Gynecol.
1970;
107
691-700
34
Slayton R, Johnson G, Brady L, Blessing J.
Radiotherapy and chemotherapy in malignant tumors of the ovarian stroma.
Proc ASCO/AACR.
1980;
21
430
35
Barlow J J, Piver M S, Chuang J T, Cortes E P, Ohnuma T, Holland J F.
Adriamycin and bleomycin, alone and in combination, in gynecologic cancers.
Cancer.
1973;
32
735-743
36
Jacobs A J, Deppe G, Cohen C J.
Combination chemotherapy of ovarian granulosa cell tumor with cisplatin and doxorubicin.
Gynecol Oncol.
1982;
14
294-297
37
Camlibel F T, Caputo T A.
Chemotherapie of granulosa cell tumors.
Am J Obstet Gynecol.
1983;
145
763-765
38 Drescher F S, Sehouli J, Buchmann E, Ricke E, Weidemann H, Lichtenegger W. Das
Rezidiv eines Granulosazelltumors - ein multiviszerales Problem! Kongressband 115.
Tagung der Norddeutschen Gesellschaft für Gynäkologie und Geburtshilfe. Greifswald;
Norddeutsche Gesellschaft für Gynäkologie und Geburtshilfe 1999: 184-185
39
Slayton R E.
Management of germ cell and stromal tumors of the ovary.
Semin Oncol.
1984;
11
299
40
Pecorelli S, Wagenaar H C, Vergote I B. et al .
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent
or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynecological Cancer
Cooperative Group study.
Eur J Cancer.
1999;
35
1331-1337
41
Lauszus F F, Petersen A C, Greisen J, Jakobsen A.
Granulosa cell tumor of the ovary: a population-based study of 37 women with stage
I disease.
Gynecol Oncol.
2001;
81
456-460
42
Homesley H D, Bundy B N, Hurteau J A, Roth L M.
Bleomycin, etoposide, and cisplatin combination therapy in ovarian granulosa cell
tumors and other stromal malignancies: a gynecologic oncology group study.
Gynecol Oncol.
1999;
72
131-137
43
Wolf J, Mullen J, Eifel P J, Burke T W, Levenback C, Gerhenson D M.
Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.
Gynecol Oncol.
1999;
73
35-41
44 Fox H, Langly F A. Granulosa and theca cell tumours of the ovary. London; Heinemann
1976: 172
45 Bühl A, Zöfel P. SPSS Version 8 Einführung in die moderne Datenanalyse unter Windows. Bonn;
Addison-Wesley-Longman 1999
46
Cutler S J, Ederer F.
Maximum utilization of the life table method in analyzing survival.
J Chronic Dis.
1958;
8
699-712
47
Kaplan E L, Meier P.
Nonparametric estimation from incomplete observations.
J Am Statist Assoc.
1958;
53
457-481
48
Cronje H S, Niemand I, Bam R H, Woodruff J D.
Review of the granulosa-theca cell tumors from the Emil Novak Ovarian Tumor Registry.
Am J Obstet Gynecol.
1999;
180
323-327
49
Hines J F, Mahmoud A K.
Recurrent granulosa cell tumor of the ovary 37 years after inital diagnosis: A case
report and review of the literature.
Gynecol Oncol.
1995;
60
484-488
50
Sex Cord-Stromal Tumors. De Vita V, Hellman S, Rosenberg S (eds) Cancer. Principles and Practice of Oncology.
6th ed. Philadelphia; Lippincott, Williams and Wilkins 2001: 1530-1531
51
Savage P, Constenla D, Fisher C. et al .
Granulosa cell tumors of the ovary: Demographics, survival and the management of advanced
disease.
Clin Oncol.
1998;
10
242-245
52
Zambetti M, Escobedo A, Pilotti S. et al .
Cisplatin vinblastine bleomycin combination chemotherapy in advanced or recurrent
granulosa cell tumors of the ovary.
Gynecol Oncol.
1990;
36
317-320
53
Pal S K, Chowdhury N N.
Late recurrence of granulosa cell tumor.
Asia Oceania J Obstet Gynaecol.
1986;
12
21-23
54
Tresukosol D, Kudelka A P, Edwards C L, Charnsangavej C, Narboni N, Kavanagh J J.
Recurrent ovarian granulosa cell tumor: a case report of dramatic response to taxol.
Int J Gynecol Cancer.
1995;
5
156-159
55
Miller B E, Barron B A, Wan J Y, Delmore J E, Silva E G, Gershenson D M.
Prognostic factors in adult granulosa cell tumor of the ovary.
Cancer.
1997;
79
1951-1955
56
Stenwig J T, Hazekamp J T, Beecham J B.
A clinicopathological study of 118 cases with long term follow-up.
Gynecol Oncol.
1979;
7
136-152
57
Anikuwe C, Dawood M Y, Kramer E.
Granulosa and theca cell tumors.
Obstet Gynecol.
1978;
51
214-220
58
Lusch C L, Mercurio T M, Runyeon W K.
Delayed recurrence and chemotherapy of a granulosa cell tumor.
Obstet Gynecol.
1978;
51
505-507
59
Schwartz P E, Smith J P.
Treatment of ovarian stromal tumors.
Am J Obstet Gynecol.
1976;
125
402-411
60
Jacobs I, Bast R C.
The CA-125 tumor-associated antigen: A review of the literature.
Hum Reprod.
1989;
4
1-12
61
Pectasides D, Alevizakos N, Athanassiou A E.
Cisplatin-containing regimen in advanced or recurrent granulosa cell tumors of the
ovary.
An Oncol.
1992;
3
316-318
62
Wabersich J, Fracas M, Mazzer S, Marchettie M, Altavilla G.
The value of prognostic factors in ovarian granulosa cell tumors.
Eur J Gynecol Oncol.
1998;
19
69-72
63
Al-Badawi I A, Basher P MA, Ghatage P. et al .
Postoperative chemotherapy in advanced ovarian granulosa cell tumors.
Int J Gynecol Cancer.
2002;
12
119-123
64
Einhorn L H, Donohue J.
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy
in disseminated testicular cancer.
Ann Intern Med.
1977;
87
293-298
65
Williams S D, Stablein D M, Einhorn L H.
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological
stage II testicular cancer.
N Engl J Med.
1987;
317
1433-1438
66
du Bois A, Neijt J P, Thigpen J T.
First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer
- a new standard of care?.
Ann Oncol.
1999;
10 (Suppl 1)
35-41
67
Pecorelli S, Wagenaar H C, Bonazzi G, Bokkel H, Kbierska A, Ploch E.
Cisplatin (P), vinblastine (V), bleomycin (B) combination chemotherapy in recurrent
or advanced granulosa(-theca) cell tumours of the ovary (GCTO): An EORTC gynecological
cancer cooperative group study.
Proc ASCO (Abstract 576).
1988;
7
147
68
Boggess J F, Soules M R, Goff B A, Greer B E, Cain J M, Tamimi H K.
Serum inhibin an disease status in woman with ovarian granulosa cell tumor.
Gynecol Oncol.
1997;
64
64-69
Dr. Jalid Sehouli
Klinik für Frauenheilkunde und Geburtshilfe Charité, Campus Virchow-Klinikum Medizinische
Fakultät der Humboldt-Universität zu Berlin
Augustenburger Platz 1
13353 Berlin
Email: sehouli@aol.com